Oncolytic virus immunotherapy: Future prospects for oncology

Journal for ImmunoTherapy of Cancer

Volumn 6, Issue 1, 2018, Pages

  Raja, Junaid ^a   Ludwig, Johannes M ^a,b   Gettinger, Scott N ^a,c   Schalper, Kurt A ^a   Kim, Hyun S ^a,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c YALE CANCER CENTER   (United States)

Author keywords

Cancer Immunoediting; Immunomodulatory oncolytic virus; Oncolytic viral vaccine; Oncolytic viruses; Tumor niche biology

Indexed keywords

CD47 ANTIGEN; FLICE INHIBITORY PROTEIN; GAMMA INTERFERON; INTERLEUKIN 10; ONCOLYTIC VIRUS; PROGRAMMED DEATH 1 LIGAND 1; CANCER VACCINE;

B CELL LYMPHOMA; BONE MARROW CELL; COLITIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DOWN REGULATION; HUMAN; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIMODALITY CANCER THERAPY; NATURAL KILLER CELL; NONHUMAN; PANCREATITIS; PNEUMONIA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR CELL; TUMOR ESCAPE; TUMOR GROWTH; UPREGULATION; ADVERSE EVENT; ANIMAL; CLASSIFICATION; GENE TRANSFER; GENE VECTOR; GENETICS; IMMUNOLOGY; IMMUNOMODULATION; NEOPLASM; ONCOLYTIC VIROTHERAPY; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; CANCER VACCINES; COMBINED MODALITY THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; IMMUNOLOGIC SURVEILLANCE; IMMUNOMODULATION; IMMUNOTHERAPY; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TREATMENT OUTCOME; TUMOR ESCAPE;

EID: 85057770076     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-018-0458-z     Document Type: Review

References (98)

1. Abi-Jaoudeh N, et al. Personalized oncology in interventional radiology. J Vasc Interv Radiol. 2013;24(8):1083-92.
2. Suzuki S, et al. Current status of immunotherapy. Jpn J Clin Oncol. 2016;46(3):191-203.
3. Papaioannou NE, et al. Harnessing the immune system to improve cancer therapy. Annals Transl Med. 2016;4(14):261.
4. Khalil DN, et al. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13(5):273-90.
5. Restifo NP, Smyth MJ, Snyder A. Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer. 2016;16(2):121-6.
6. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012;12(4):269-81.
7. Orange M, Reuter U, Hobohm U. Coley's lessons remembered. Integr Cancer Ther. 2016;15(4):502-11.
8. Lomax AJ, McNeil C. Acute management of autoimmune toxicity in cancer patients on immunotherapy: common toxicities and the approach for the emergency physician. Emerg Med Australas. 2017;29(2):245-51.
9. Seton-Rogers S. Immunotherapy: powerful combinations. Nat Rev Cancer. 2016;16(12):757.
10. Lichty BD, et al. Going viral with cancer immunotherapy. Nat Rev Cancer. 2014;14(8):559-67.
11. Matsueda S, Graham DY. Immunotherapy in gastric cancer. World J Gastroenterol. 2014;20(7):1657-66.
12. Drakes ML, Stiff PJ. Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy. Immunotargets Ther. 2014;3:151.
13. Antonarakis ES. Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer. Asian J Androl. 2012;14(4):520.
14. Melcher A, et al. Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther. 2011;19(6):1008-16.
15. Russell SJ, Peng K-W, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30(7):658-70.
16. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137-48.
17. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024):1565-70.
18. Shankaran V, et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410(6832):1107-11.
19. O'Sullivan T, et al. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med. 2012;209(10):1869-82.
20. Burnet F. An immunological approach to ageing. Lancet. 1970;296(7668):358-60.
21. Slaney CY, Rautela J, Parker BS. The emerging role of immunosurveillance in dictating metastatic spread in breast cancer. Cancer Res. 2013;73(19):5852-7.
22. Hamai A, et al. Immune surveillance of human cancer: if the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune? Tissue Antigens. 2010;75(1):1-8.
23. Ribatti D. The concept of immune surveillance against tumors: the first theories. Oncotarget. 2017;8(4):7175.
24. Rilke F, et al. Prognostic significance of her-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer. 1991;49(1):44-9.
25. Lipponen P, et al. Tumour infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer. Eur J Cancer. 1993;29(1):69-75.
26. Clemente CG, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77(7):1303-10.
27. Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene. 2008;27(45):5932-43.
28. Messerschmidt JL, Prendergast GC, Messerschmidt GL. How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances. Oncologist. 2016;21(2):233-43.
29. Mohme M, Riethdorf S, Pantel K. Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape. Nat Rev Clin Oncol. 2017;14.3:155.
30. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007;117(5):1137-46.
31. Campoli M, Chang C-C, Ferrone S. HLA class I antigen loss, tumor immune escape and immune selection. Vaccine. 2002;20:A40-5.
32. Zhang Q, et al. Adoptive transfer of tumor-reactive transforming growth factor-β-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res. 2005;65(5):1761-9.
33. Chen M-L, et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo. Proc Natl Acad Sci U S A. 2005;102(2):419-24.
34. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nat Med. 2001;7(10):1118-22.
35. Kataoka T, et al. FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. J Immunol. 1998;161(8):3936-42.
36. Hinz S, et al. Bcl-XL protects pancreatic adenocarcinoma cells against CD95-and TRAIL-receptor-mediated apoptosis. Oncogene. 2000;19(48):5477.
37. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329-60.
38. Terabe M, Berzofsky JA. Immunoregulatory T cells in tumor immunity. Curr Opin Immunol. 2004;16(2):157-62.
39. Dong H, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793-800.
40. Schwartz RH. T cell anergy. Annu Rev Immunol. 2003;21(1):305-34.
41. Tripathi P, Agrawal S. Non-classical HLA-G antigen and its role in the cancer progression. Cancer Investig. 2006;24(2):178-86.
42. Derré L, et al. Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J Immunol. 2006;177(5):3100-7.
43. Mantovani A, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549-55.
44. Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology. 2007;121(1):1-14.
45. Birkeland SA, et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer. 1995;60(2):183-9.
46. Liu B, et al. ICP34. 5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10(4):292-303.
47. Bommareddy, Praveen K., et al. Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma. Am J Clin Dermatol. 2017;18.1:1-15.
48. Goldufsky J, et al. Oncolytic virus therapy for cancer. Oncolytic Virother. 2013;2:31-46.
49. Larocca C, Schlom J. Viral Vector-based Therapeutic Cancer Vaccines. Cancer J. 2011;17(5):359.
50. Madan RA, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(5):501-8.
51. Parato KA, et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther. 2012;20(4):749-58.
52. Xie Y, et al. Immunotherapy for hepatocellular carcinoma: current advances and future expectations. J Immunol Res. 2018;2018:8740976.
53. Breitbach CJ, et al. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res. 2013;73(4):1265-75.
54. Yoo SY, et al. Evolutionary cancer-favoring engineered vaccinia virus for metastatic hepatocellular carcinoma. Oncotarget. 2017;8(42):71489.
55. Miyamoto S, et al. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res. 2012;72(10):2609-21.
56. Yaacov B, et al. Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors. Cancer Gene Ther. 2008;15(12):795-807.
57. Liu T-C, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Rev Clin Oncol. 2007;4(2):101.
58. Cukier-Meisner E. INFECTIOUS ENTHUSIASM. Biocentury. FEB 29, 2016. https://www.biocentury.com/biocentury/product-development/2016-02-29/how-oncolytic-viruses-are-coming-age-cancer-immunotherapy.
59. Breitbach CJ, Lichty BD, Bell JC. Oncolytic viruses: therapeutics with an identity crisis. EBioMedicine. 2016;9:31-6.
60. Health, U.S.N.I.o. ClinicalTrials.gov. 2017 [cited 2017; Available from: http://www.clinicaltrials.gov. Accessed 11 2017.
61. Senzer NN, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27(34):5763-71.
62. Eager R, Nemunaitis J. Clinical development directions in oncolytic viral therapy. Cancer Gene Ther. 2011;18(5):305-17.
63. Park B-H, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 2008;9(6):533-42.
64. Zamarin D, et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Total Environ. 2014;6(226):226ra32.
65. Kaufman HL, et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol. 2010;17(3):718-30.
66. Andtbacka, R.H.I., et al. OPTiM: a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. in ASCO Annual Meeting Proceedings. 2013.
67. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642.
68. Barton KN, et al. Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol Ther. 2008;16(10):1761-9.
69. Liikanen I, et al. Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy. Oncoimmunology. 2015;4(3):e989771.
70. Huang B, et al. Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1. Gene Ther. 2011;18(2):164-72.
71. Breitbach CJ, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature. 2011;477(7362):99-102.
72. Mastrangelo MJ, Maguire HC, Lattime EC. Intralesional vaccinia/GM-CSF recombinant virus in the treatment of metastatic melanoma. Cancer Gene Therapy. 2002:391-400. Boston: Springer.
73. Ji R-R, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother. 2012;61(7):1019-31.
74. Spranger S, et al. Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci Total Environ. 2013;5(200):200ra116.
75. Amsen D, et al. Tissue-resident memory T cells at the center of immunity to solid tumors. Nat Immunol. 2018:1.
76. Ringelhan M, et al. The immunology of hepatocellular carcinoma. Nat Immunol. 2018:1.
77. Zaretsky JM, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819-29.
78. Kaplan DH, et al. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci. 1998;95(13):7556-61.
79. Dunn GP, et al. IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res. 2005;65(8):3447-53.
80. Puzanov I, et al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol. 2016;34(22):2619-26.
81. Long GV, et al. Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma. Proc Am Soc Clin Oncol. 2016:9568-9568.
82. Ribas A, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109-1119. e10.
83. Chesney J, et al., Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. J Clin Oncol. 2017:9509-9509. https://doi.org/10.1200/JCO.2017.35.15-suppl.9509
84. Ribas A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315(15):1600-9.
85. Restifo NP, et al. Loss of functional beta2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst. 1996;88(2):100-8.
86. Sucker A, et al. Genetic evolution of T-cell resistance in the course of melanoma progression. Clin Cancer Res. 2014;20(24):6593-604.
87. d'Urso C, et al. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Investig. 1991;87(1):284.
88. Le DT, et al. Safety and survival with GVAX pancreas prime and Listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015;33(12):1325-33.
89. Le DT, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother. 2013;36(7):382.
90. De Silva N, et al. Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses. Cytokine Growth Factor Rev. 2010;21(2):135-41.
91. Underhill DM, Ozinsky A. Phagocytosis of microbes: complexity in action. Annu Rev Immunol. 2002;20(1):825-52.
92. Goldberg SN, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria 1. Radiology. 2005;235(3):728-39.
93. Nagy JA, et al. Permeability properties of tumor surrogate blood vessels induced by VEGF-A. Lab Investig. 2006;86(8):767-80.
94. Nagy JA, Dvorak HF. Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets. Clin Exp Metastasis. 2012;29(7):657-62.
95. Farnsworth R, et al. Vascular remodeling in cancer. Oncogene. 2014;33(27):3496-505.
96. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011;10(6):417-27.
97. Jacobs A, et al. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet. 2001;358(9283):727-9.
98. Dingli D, Russell SJ, Morris JC. In vivo imaging and tumor therapy with the sodium iodide symporter. J Cell Biochem. 2003;90(6):1079-86.